Gini Fleming to Aromatase Inhibitors
This is a "connection" page, showing publications Gini Fleming has written about Aromatase Inhibitors.
Connection Strength
1.436
-
Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015 04 23; 372(17):1673.
Score: 0.493
-
Adjuvant aromatase inhibitors: are we there yet? Cancer. 2003 Nov 01; 98(9):1779-81.
Score: 0.222
-
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med. 2018 Jul 12; 379(2):122-137.
Score: 0.153
-
Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. J Clin Oncol. 2017 Sep 20; 35(27):3113-3122.
Score: 0.143
-
Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015 Jan 29; 372(5):436-46.
Score: 0.120
-
Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials. Breast. 2013 Dec; 22(6):1094-100.
Score: 0.111
-
Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA. 2009 Aug 19; 302(7):774-80.
Score: 0.083
-
Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. J Am Coll Surg. 2009 May; 208(5):906-14; discussion 915-6.
Score: 0.081
-
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014 Jul 10; 371(2):107-18.
Score: 0.029